文献速递骨软组织肉瘤与黑色素瘤

TK216治疗尤文肉瘤的开放标签、多中心、I/II期首次人体试验:第一代EWS::FLI1融合蛋白拮抗剂

Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.
PubMed 文献 · J Clin Oncol · 2024-07-02

这项开放标签、多中心、I/II期首次人体试验评估了TK216在复发/难治性尤文肉瘤患者中的安全性、耐受性和疗效。85例患者入组,14天持续输注TK216 200 mg/m2每日一次被确定为最大耐受剂量和II期推荐剂量;在II期推荐剂量下常见不良事件为中性粒细胞减少(44.7%)等,第9和10队列中2例完全缓解、1例部分缓解、14例疾病稳定,6个月无进展生存率为11.9%,第11队列8例无缓解。结论认为TK216 14天持续输注±长春新碱耐受性良好,在II期推荐剂量下对复发/难治性尤文肉瘤活性有限。

要点

  • TK216为直接结合EWS::FLI1的第一代融合蛋白拮抗剂,联合长春新碱在临床前模型显示协同活性。
  • 14天持续输注TK216 200 mg/m2每日一次为最大耐受剂量和II期推荐剂量(第9队列确定)。
  • II期推荐剂量下常见相关不良事件包括中性粒细胞减少44.7%、贫血29.4%、白细胞减少29.4%、发热性中性粒细胞减少15.3%、血小板减少11.8%、感染17.6%。

核心结论

  • TK216以14天持续输注给药、联合或不联合长春新碱,耐受性良好,在复发/难治性尤文肉瘤的II期推荐剂量下活性有限。

研究设计与样本

  • 开放标签、多中心、I/II期首次人体试验,采用3+3设计并在II期推荐剂量下扩展队列,共入组85例复发/难治性尤文肉瘤患者。
  • TK216经静脉持续输注,分11个队列,输注时长由7天 later 延长至10、14和28天;第2周期后第1天可根据研究者选择加用长春新碱。

主要发现

  • 患者中位年龄27岁(范围11-77),既往中位全身治疗方案数为三线(范围1-10)。
  • 14天输注TK216 200 mg/m2每日一次的最大耐受剂量在第9队列确定,并选为II期推荐剂量。
  • 在II期推荐剂量下治疗患者中最常见的相关不良事件包括中性粒细胞减少(44.7%)、贫血(29.4%)、白细胞减少(29.4%)、发热性中性粒细胞减少(15.3%)、血小板减少(11.8%)和感染(17.6%)。
  • 第9和10队列中,2例患者完全缓解、1例部分缓解、14例疾病稳定,6个月无进展生存率为11.9%。
  • 第11队列8例患者中无缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ewing Sarcoma (ES), a rare cancer with a pathognomonic translocation resulting in the Ewing sarcoma gene (EWS)::FLI1 oncoprotein, has a poor prognosis in the relapsed/refractory (R/R) setting. Tokalas (TK)216 was designed to bind EWS::FLI1 proteins directly, disrupt protein-protein interactions, and inhibit transcription factor function. TK216 plus vincristine showed synergistic activity in preclinical tumor models. To our knowledge, we report the results of a first-in-class, first-in-human phase I/II trial of TK216 in R/R ES. PATIENTS AND METHODS: TK216 was administered intravenously as a continuous infusion to patients with R/R ES in 11 cohorts. The dosing duration of 7 days was later extended to 10, 14, and 28 days. Vincristine could be added on day 1 after cycle 2, per investigators' choice. The trial used a 3 + 3 design with an expansion cohort at the recommended phase II dose (RP2D). RESULTS: A total of 85 patients with a median age of 27 years (range, 11-77) were enrolled. The maximum tolerated dose for the 14-day infusion of TK216, 200 mg/m2 once daily, was determined in cohort 9 and selected as the RP2D. The median previous number of systemic therapies regimens was three (range, 1-10). The most frequent-related adverse events in patients treated at the RP2D included neutropenia (44.7%), anemia (29.4%), leukopenia (29.4%), febrile neutropenia (15.3%), thrombocytopenia (11.8%), and infections (17.6%). In cohorts 9 and 10, two patients had a complete response, one had a partial response, and 14 had stable disease; the 6-month progression-free survival was 11.9%. There were no responses among the eight patients in cohort 11. CONCLUSION: TK216 administered as 14-day continuous infusion with or without vincristine was well tolerated and showed limited activity at the RP2D in R/R ES.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Meyers PA, Federman N, Daw N, et al. Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. J Clin Oncol. 2024. PMID: 38954782. doi:10.1200/JCO.24.00020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。